Genenta Science S.p.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GNTA research report →
Price Chart
About the company
Genenta Science S. p. A.
- CEO
- Pierluigi Paracchi
- IPO
- 2021
- Employees
- 9
- HQ
- Milan, MI, IT
Get TickerSpark's AI analysis on GNTA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $22.78M
- P/E
- -3.09
- Fwd P/E
- 1.70
- PEG
- -0.09
- P/S
- 0.00
- P/B
- 0.99
- EV/EBITDA
- -3.69
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -36.82%
- ROIC
- -21.33%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-26,973+42.0%
- Op Income
- $-6,343,107
- Net Income
- $-6,272,111+32.6%
- EPS
- $-0.33+32.7%
- OCF Growth
- -10.1%
- FCF Growth
- -10.1%
- 52W High
- $10.00
- 52W Low
- $0.55
- 50D MA
- $1.56
- 200D MA
- $1.29
- Beta
- 0.77
- RSI (14)
- 37
- Avg Volume
- 1.48M
No earnings-call transcripts are available for GNTA yet.
- Free Float
- 72.4%
- Shares Outstanding
- 19.15M
- Float Shares
- 13.87M
of shares held by institutions
15 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | Paracchi Pierluigi | other | 100,000 |
| Mar 30, 26 | Galimi Francesco | other | 20,000 |
| Mar 30, 26 | PARACCHI GIACOMOANTONIO | other | 20,000 |
| Mar 30, 26 | Sharei Armon | other | 20,000 |
| Mar 30, 26 | Mutti Miguel Maria | other | 20,000 |
| Mar 30, 26 | SLANSKY RICHARD B | other | 80,000 |
| Mar 18, 26 | PARACCHI GIACOMOANTONIO | other | 0 |
| Mar 18, 26 | PARACCHI GIACOMOANTONIO | other | 0 |
| Jun 4, 25 | Sharei Armon | other | 20,000 |
| Mar 18, 26 | Sharei Armon | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GNTA coverage
Recent articles, reports, and earnings notes.
No research on GNTA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GNTA report →Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm
globenewswire.com · Jul 23
Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results
globenewswire.com · Jul 22
Genenta signs Definitive Agreements with Sophia High Tech
globenewswire.com · Apr 23
Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs
globenewswire.com · Mar 27
Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini
globenewswire.com · Mar 24
Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University
globenewswire.com · Mar 13
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
globenewswire.com · Feb 27
Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator
globenewswire.com · Jan 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.